1.Accrual Hits 400 and SUPREMO opens in Singapore and Japan

The 400th patient was randomised to SUPREMO on 14th May 2009. The National Cancer Centre, Singapore and Komagome Hospital, Japan opened to recruitment on March 09 and June 09 respectively. The recent Kyoto Breast Cancer Consensus Conference statement will be encouraging entry of patients with 1-3 involved nodes after mastectomy into a randomised trial, complimenting the recent St Gallen consensus statement on this group of patients.

2. NICE guidance encourages recruitment into SUPREMO trial

Please see below for text extract from recent NICE guidance:

CG80 Early and locally advanced breast cancer: NICE guideline, 25 February 2009 on early and advanced breast cancer that encourages recruitment in the SUPREMO adjuvant radiotherapy trial:

Radiotherapy after mastectomy
1.1.1           Offer adjuvant chest wall radiotherapy to patients with early invasive breast cancer who have had a mastectomy and are at a high risk of local recurrence. Patients at a high risk of local recurrence include those with four or more positive axillary lymph nodes or involved resection margins.

1.1.2           Consider entering patients who have had a mastectomy for early invasive breast cancer and who are at an intermediate risk of local recurrence into the current UK trial (SUPREMO) assessing the value of postoperative radiotherapy. Patients at an intermediate risk of local recurrence include those with one to three lymph nodes involved, lymphovascular invasion, histological grade 3 tumours, ER-negative tumours, and those aged under 40.

1.1.3           Do not offer radiotherapy following mastectomy to patients with early invasive breast cancer who are at low risk of local recurrence (for example, most patients who are lymph node-negative).